UK - Department of Health and Social Care (DHSC)
Global Antimicrobial Resistance Innovation Fund (GAMRIF) – Accelerating Antibacterial Innovation with CARB-X
Programme Data Last Updated: 27/07/2021
IATI Identifier: GB-GOV-10-GAMRIF-WP2-CARB-X
Through the Global AMR Innovation Fund (GAMRIF), the UK Department of Health and Social Care (DHSC) has invested £20 million over three years in Boston University’s Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), which is a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This contribution will invest in high-value, innovative research to accelerate the development of products to reduce the harm from drug-resistant infections.Description
The aim of this project is to invest in high-value, innovative research to accelerate the development of products up to and including Phase I to reduce the harm to human health, welfare and economic growth from drug-resistant infections. In particular, the programme will focus on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in low- and middle-income countries (LMICs).Description
Projects funded through GAMRIF will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.
A comparison across financial years of forecast budget and spend to date on the Programme.